Drug Database
Back to search

Belgium· BE-AMP-SAM662020-00

Takhzyro 150 mg

A lanadelumab product containing lanadelumab, registered in Belgium by Takeda Pharmaceuticals International Ireland Branch. The same ATC class is registered in 15 of our 19 countries.

ATC B06AC05

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedTakhzyro 150 mgATCB06AC05REGISTER NO.BE-AMP-SAM662020-00PACKS LISTED1CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lanadelumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lanadelumab is registered in 15 of 19 countries.

Countries holding a registration under ATC B06AC05 (lanadelumab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 10 of them publish a price we can compare per daily dose
Search lanadelumab products by name

Lanadelumab · ATC B06AC05

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lanadelumab costs, country by country.

Normalised to the WHO defined daily dose (21.4 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Lanadelumab · price per daily dose (21.4 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$857.11
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Lanadelumab
Manufacturer
Takeda Pharmaceuticals International Ireland Branch
Country
Belgium (BE)
ATC code
B06AC05
ATC class
Lanadelumab
Defined daily dose
21.4 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 1

  • be_apb
    4857017

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Lanadelumab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lanadelumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Takhzyro
  • Liechtenstein · Takhzyro
  • Norway · Takhzyro

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/84a641e0-bc9e-44bb-be96-99c3ac9dd24c
GET /v1/drugs/84a641e0-bc9e-44bb-be96-99c3ac9dd24c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection in pre-filled syringe",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Takhzyro 150 mg",
  "name_fr": "Takhzyro 150 mg",
  "name_nl": "Takhzyro 150 mg",
  "amp_code": "SAM662020-00",
  "strengths": [
    "150.0000",
    "150.0000"
  ],
  "pack_count": 3,
  "substances": [
    "Lanadelumab",
    "Disodium Hydrogen Phosphate Dihydrate",
    "Sodium Chloride",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Lanadelumab",
  "authorisation_numbers": [
    "EU/1/18/1340/009",
    "EU/1/18/1340/007",
    "EU/1/18/1340/008"
  ]
}
API referenceMCP serverPlans

See everything about lanadelumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console